Effects of immunosuppressants on concanavalin A-induced interleukin-2 mRNA expression in mouse liver.
Treatment of mice with concanavalin A (Con A) induced interleukin-2 (IL-2) mRNA expression in the liver, which might be a result of Con A-induced T-cell activation. Pretreatment with cyclosporine A (CsA) (50 mg/kg, i.p.) or dexamethasone (DEX) (2.5 mg/kg, i.p.) inhibited the Con A-induced liver injury, as assessed by the plasma alanine aminotransferase level, by 85% and 95%, respectively. CsA inhibited the Con A-induced IL-2 mRNA expression completely, whereas DEX only partially inhibited it. Thus CsA seems to prevent Con A-induced hepatitis mainly by inhibiting T-cell activation. In the case of DEX, rather than by inhibiting Con A-induced T-cell activation, it may prevent Con A-induced hepatitis through other means.
Okamoto
T
T
Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama, Japan.
Kobayashi
T
T
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control; D003208:Concanavalin A / Q000037:antagonists & inhibitors / Q000633:toxicity*; D016572:Cyclosporine / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D012333:RNA, Messenger / Q000235:genetics*
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D012333:RNA, Messenger; D003208:Concanavalin A; D003907:Dexamethasone; D016572:Cyclosporine